Could Augmented Reality With Biofeedback Be Beneficial In Improvement Of Motor And Non-motor Symptoms In Patients With Parkinson’s Disease?
Objective: The assessment of the biofeedback and AR training effects in patients with Parkinson's disease (PD) is worth exploring. Background: Parkinson disease (PD) is a…Gender Disparities in Quality of Life Domains Among Hispanic Individuals with Parkinson’s Disease: A Comparative Analysis
Objective: This study aims to determine gender differences in the quality of life of Parkinson's disease (PD) among Hispanic individuals. Background: PD profoundly affects various…Deep Brain Stimulation From the Perspective of Relatives and Caregivers: A Qualitative Analysis and Caregiver Burden
Objective: One of the most important conditions for success in Deep brain stimulation (DBS), which has been proven effective for more than thirty years and…Participant-reported personal utility of genetic testing for Parkinson’s disease and interest in clinical trial participation
Objective: To investigate whether participants in the PD GENEration study (NCT04994015) perceived personal benefit from receiving genetic testing for Parkinson’s disease (PD), whether being tested…ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
Objective: Here we describe ORION, a phase 3 trial assessing efficacy and safety of AMX0035 in progressive supranuclear palsy (PSP). Background: PSP is a rare,…Sleep disorders in Parkinson’s disease
Objective: to specify the clinical features of sleep disorders in patients with PD and their impact on quality of life indicators; assessment of the relationship…Assembling a Cohort of Hyposmic Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention
Objective: The goal of this project was to amass a cohort of individuals with hyposmia to later invite them to participate in clinical trials for…Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612
Objective: Characterize dopaminergic treatment-emergent adverse events (TEAEs) reported with 24h ND0612 treatment in clinical studies. Background: Dopaminergic adverse events are commonly reported across the spectrum…NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…ENLITE PD – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease
Objective: To determine if either once or twice-daily bright white light therapy (BWLT) improves sleep sufficiently relative to two control LT conditions to warrant proceeding…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.